287 results about "Pharmaceutical packaging" patented technology

Methods and compositions are disclosed for the preparation of free radical scavenging polymers and polymer films functionalized with antioxidants. Enzymatic and chemical tailoring of monomers with antioxidants followed by enzymatic polymerization is described. These antioxidant functionalized polymers can increase shelf life and quality of food products, as well as, increase effectiveness of pharmaceutical agents when used as packaging or as coatings on packaging for oxygen sensitive materials. The novel enzymatic covalent coupling of antioxidants to a polymer enhances the free radical scavenging ability of packaging while also inhibiting the escape of the antioxidants, and thus limiting exposure and/or absorption by an individual. In addition to its use in food or pharmaceutical packaging, methods are disclosed for using the antioxidant coupled polymers in a variety of applications including as coatings on the inside of medical devices, such as stents and catheters, which would substantially reduce free radical damage and/or oxygen depletion during medical procedures. Furthermore, through the coupling of antioxidants to biodegradable polymers, controlled delivery and sustained release of an antioxidant to a subject is possible.

Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation from a secondary module. In a preferred embodiment the first and second pharmaceutical formulations are separated from one another in a three piece capsule, a capsule-in-a-capsule or a tablet-in-a-capsule, and the primary and secondary modules are interchangeable.

The present invention relates generally to a pharmaceutical packaging for increasing the product shelf life, reducing discoloration, and reducing degradation of pharmaceuticals by reducing the oxygen level present in the pharmaceutical package. The pharmaceutical package comprises a substantially oxygen impermeable container, at least one oxygen scavenging element disposed in the container, and at least one packaged pharmaceutical product disposed in the oxygen impermeable container.

A method of preparing a macromolecule deterrent surface on a pharmaceutical package. In particular, the present invention relates to a method of preparing a protein deterrent surface on a pharmaceutical package by applying a coating or coatings directly to the pharmaceutical package that reduces the adsorption of proteins onto pharmaceutical packaging while not affecting the activity of the protein solution contained.

A high silica glass composition comprising about 82 to about 99.9999 wt. % SiO₂ and from about 0.0001 to about 18 wt. % of at least one dopant selected from Al₂O₃, CeO₂, TiO₂, La₂O₃, Y₂O₃, Nd₂O₃, other rare earth oxides, and mixtures of two or more thereof. The glass composition has a working point temperature ranging from 600 to 2,000° C. These compositions exhibit stability similar to pure fused quartz, but have a moderate working temperature to enable cost effective fabrication of pharmaceutical packages. The glass is particularly useful as a packaging material for pharmaceutical applications, such as, for example pre-filled syringes, ampoules and vials.

A disease management system including: a Diagnostic Module, which provides access to patient information and scientific guidelines for patient treatment; a Diagnostic Interpretive Module, which provides tools to evaluate risk of particular diseases or conditions based on patient information and an evaluative methodology; a Prescriptive Module, which is used to recommend, select, and/or evaluate one or more treatment regimens based on patient information and guidelines; a Dispensing Module, which evaluates a patient's compliance with a treatment regimen; and/or a Feedback and Patient Management Module, which gathers compliance information and evaluates efficacy of a treatment regimen for a patient. In embodiments of the subject invention, some or all of the modules described can communicate to manage a disease, medical condition, and/or health problem in a patient.

The invention provides an edible collagen food packaging film and a preparation method thereof. The preparation method comprises the following steps: firstly, stirring a 5-30wt% collagen solution and a 0.1-3wt% modifier solution at the temperature of 30-60 DEG C to react for 30-60 minutes, thus obtaining a compound solution; then adding a plasticizer and an auxiliary additive into the compound solution, then continuing to stir for 20-40 minutes at the temperature of 30-60 DEG C so as to obtain a mixed solution; and pouring the mixed solution in a die, molding, drying for 5-15 hours at the temperature of 40-80 DEG C, so as to obtain the edible collagen food packaging film. The edible collagen food packaging film has the advantages of better mechanical property, better heat stability, better moisture barrier property, safety, effectiveness and no side effect; wastes can be degraded and do not cause environment pollution; and the edible collagen food packaging film can be widely applied to the fields of various food packaging and medicament packaging, and has a good market application prospect.

The invention discloses a method for the production of packaging made from borosilicate glass for pharmaceutical products and medical products comprising the steps of: providing a glass tube made from a borosilicate base glass, generating a temporary interface layer on an inner surface of the glass tube, hot-forming the glass tube at a temperature above T_g, and cooling down the glass tube to room temperature.

An automated pharmaceutical product packaging machine simultaneously fills a plurality of product package templates in parallel with desired pharmaceutical dosing requirements. The templates are subsequently positioned over a temporary storage template having cavities for receiving solid pharmaceutical doses. A collector member is subsequently placed beneath the temporary storage template for receiving the pharmaceuticals which in turn is positioned over a solid pharmaceutical product package having a plurality of cavities which correspond to openings on the templates and wherein each of the templates fills a pharmaceutical package.

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing ErbB, as determined by a gene amplification assay, with an ErbB antagonist. Such method comprises administering a cancer-treating dose of the ErbB antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells ErbB has been found to be amplified e.g., by fluorescent in situ hybridization. ErbB antagonists described include an anti-HER2 antibody. Pharmaceutical packaging for providing the components for such treatment is also provided.

The invention relates to a pharmaceutical packaging comprising a silicone-free lubricating film of crosslinked organic molecules, and to a method for producing same.

Disclosed are methods for marking a pharmaceutical product, container or pharmaceutical packaging system with a scent to establish the identity and/or source of the pharmaceutical.

The invention relates to a biodegradable multilayer material, which can be a thin film material or a sheet material. The biodegradable multilayer material at least comprises one of an adipic butanediol terephthalate copolymer (PBAT)/PBAT-chain extender-polypropylene carbonate (PBAT-Co-PPC)/PPC blend layer, a PBAT/PBAT-chain extender-polylactic acid (PBAT-Co-PLA)/PLA blend layer and a PBAT/PBAT-chain extender-polyhydroxyalkanoate (PBAT-Co-PHA)/PHA blend layer, and blend resins are respectively prepared through twin-screw reactive extrusion. The multilayer material is produced by using extrusion and coextrusion methods, has a function that the transmission rates of oxygen, carbon dioxide and water vapor can be adjusted, and can be applied to the packaging field and the agriculture field, and especially applied to food packaging, pharmaceutical packaging, and ground film mulching.

A disease management system including: a Diagnostic Module, which provides access to patient information and scientific guidelines for patient treatment; a Diagnostic Interpretive Module, which provides tools to evaluate risk of particular diseases or conditions based on patient information and an evaluative methodology; a Prescriptive Module, which is used to recommend, select, and/or evaluate one or more treatment regimens based on patient information and guidelines; a Dispensing Module, which evaluates a patient's compliance with a treatment regimen; and/or a Feedback and Patient Management Module, which gathers compliance information and evaluates efficacy of a treatment regimen for a patient. In embodiments of the subject invention, some or all of the modules described can communicate to manage a disease, medical condition, and/or health problem in a patient.

The invention belongs to the field of papermaking technology, and particularly relates to a plastic-free environment-friendly isolation paper and a plastic-free environment-friendly release paper used for the industry fields of food hygiene, pharmaceutical packaging, electronic appliances, household products, cosmetics, supermarket logistics, post express and the like and a preparation method of the plastic-free environment-friendly isolation paper and the plastic-free environment-friendly release paper. The technical scheme is as follows: the isolation paper is composed of a 30-60g/m<2> low-weight tissue paper or a 50-200g/m<2> cultural paper, and a precoating layer and an isolation layer coated in sequence on the tissue or cultural paper surface, wherein a layer of precoating is coated on the front face of the base paper firstly and then a layer of isolation layer is coated into the precoating layer; the release paper is formed by coating a solvent-free silicone oil onto the isolation paper and comprises the base paper layer, the precoating layer, the isolation layer and the silicone oil layer from top to bottom in sequence. The paper prepared by the method provided by the invention has the characteristics of low requirements for base paper performance, good isolation (release) effect, high paper smoothness, no pollution, easiness of recycling, stable properties and the like. The production process has the advantages of low manufacture cost, high production efficiency, easiness of mass production and the like.

The invention relates to a pharmaceutical neutral borosilicate glass. The pharmaceutical neutral borosilicate glass comprises the following components (in weight percentage, based on oxides): 70.0-80.0% of SiO2, 7.0-12.0% of B2O3, 1.5-5.0% of Al2O3, 5.5-8.0% of Na2O, 0-1.0% of K2O, 0-1.5% of Li2O, 1.5-3.0% of CaO, 0-3.5% of BaO, 0-2.0% of MgO, 0.3-0.5% of NaCl, 6.0-9.5% of Na2O+K2O+Li2O and 1.5-6% of CaO+BaO+MgO. The pharmaceutical neutral borosilicate glass is in line with a national standard of pharmaceutical packaging containers (materials) YBB00022005-2, and is suitable for being used as pharmaceutical primary packaging materials, such as ampoules, portable bottles, penicillin bottles and the like.